Neuroimaging advances presented at AAIC 2026 demonstrated significant progress in both PET tracers and MRI techniques for Alzheimer's disease (AD) diagnosis, staging, and treatment monitoring.
New tau PET tracers with improved properties were highlighted:
- Improved specificity: Reduced off-target binding in basal ganglia and white matter
- Broadened disease utility: Applicability to primary age-related tauopathy (PART) and chronic traumatic encephalopathy (CTE)
- Kinetic modeling: Simplified quantification methods for clinical use
Tau PET quantification methods for anti-amyloid and anti-tau therapeutics:
- Regional tau burden as stratification biomarker
- Change metrics for treatment response assessment
- Correlation with cognitive outcomes
Next-generation amyloid PET tracers offer advantages:
- Faster kinetics enabling same-day imaging
- Improved signal-to-noise ratio
- Reduced non-specific binding
Standardization advances in amyloid PET:
- Centiloid scale adoption across studies
- Harmonized SUVr methods
- Longitudinal change thresholds
Emerging tracers for synaptic density:
- [^11C]UCB-J: SV2A imaging showing synaptic loss in AD
- Correlation with cognitive performance
- Potential for treatment monitoring
TSPO and novel microglial imaging targets:
- Third-generation TSPO tracers with reduced variability
- P2X7 receptor imaging for targeted neuroinflammation
- Correlation with disease progression
New quantitative approaches for clinical implementation:
- QSM (Quantitative Susceptibility Mapping): Iron deposition tracking
- MT (Magnetization Transfer): Myelin integrity assessment
- Diffusion MRI: Microstructural change detection
Advancements in fMRI for AD:
- Resting-state connectivity alterations in preclinical AD
- Default mode network (DMN) changes as early markers
- Task-based fMRI for cognitive reserve assessment
¶ Amyloid and Tau MRI
Emerging techniques for tau pathology visualization:
- T1rho imaging sensitive to tau accumulation
- MT saturation changes correlating with tau
- Diffusion changes in tau-affected regions
Chemical exchange saturation transfer for amyloid detection:
- Promising results in human studies
- Correlation with PET amyloid imaging
- Potential for widespread clinical use
Ultra-high-field MRI capabilities:
- Improved resolution for small vessel detection
- Leptomeningeal collaterals visualization
- Perivascular space characterization
Vessel wall MRI innovations:
- Distinguishing amyloid angiopathy from vasculitis
- Plaque inflammation detection
- Treatment response monitoring
Combined PET/MRI advances presented at AAIC 2026:
- Simultaneous acquisition protocols
- Attenuation correction improvements
- Multiparametric biomarkers from single session
¶ Tau-PET and Structural MRI
Combined analysis approaches:
- Tau burden prediction of atrophy patterns
- Regional vulnerability mapping
- Progression modeling
¶ Standardization Efforts
Critical progress toward clinical implementation:
- Automated analysis pipelines (FreeSurfer, FSL, ANTs)
- Harmonization across scanner vendors
- Quality control protocols
Current clinical tracers and their applications:
- [^18F]Florbetapir (Amyvid): Amyloid PET](/biomarkers/florbetapir)
- [^18F]Flutemetamol (Vizamyl): Amyloid PET](/biomarkers/flutemetamol)
- [^18F]Florbetaben (Neuraceq): Amyloid PET](/biomarkers/florbetaben)
- [^18F]Flortaucipir (Tauvid): Tau PET
Multimodal biomarker approaches:
- Amyloid PET + tau PET + MRI combinations
- Fluid biomarker correlation with imaging
- Prediction models using integrated biomarkers
Imaging endpoints in clinical trials:
- Amyloid clearance rates
- Tau spreading inhibition
- Atrophy modification
The imaging field is advancing toward:
- Early detection: Subtle changes in preclinical populations
- Personalized medicine: Individualized biomarker profiles
- Therapeutic monitoring: Surrogate endpoints for drug development
- Accessibility: Broader access to advanced imaging techniques
This page provides information about AAIC 2026: Imaging Advances.